Le H Hua1, Jeffrey A Cohen1. 1. Lou Ruvo Center for Brain Health (LHH), Cleveland Clinic, Las Vegas, NV; and Mellen Center for Multiple Sclerosis Treatment and Research (JAC), Cleveland Clinic, Cleveland, OH.
Abstract
PURPOSE OF REVIEW: Medication prices are a major contributor to the high cost of care for multiple sclerosis (MS). The patents for some of the initial injectable therapies for relapsing MS recently expired, permitting development, regulatory approval, and marketing of generic alternatives with the potential for lower prices and cost savings to payers and patients. RECENT FINDINGS: A generic version of glatiramer acetate 20 mg administered by daily subcutaneous injection recently received regulatory approval in the United States. Two additional generic versions of glatiramer acetate have been submitted for regulatory review. The development and testing of generic disease-modifying therapies for MS such as glatiramer acetate, which are complex molecules, present several complicating factors. SUMMARY: This article provides background on the development of generics and reviews the status of generic glatiramer acetate.
PURPOSE OF REVIEW: Medication prices are a major contributor to the high cost of care for multiple sclerosis (MS). The patents for some of the initial injectable therapies for relapsing MS recently expired, permitting development, regulatory approval, and marketing of generic alternatives with the potential for lower prices and cost savings to payers and patients. RECENT FINDINGS: A generic version of glatiramer acetate 20 mg administered by daily subcutaneous injection recently received regulatory approval in the United States. Two additional generic versions of glatiramer acetate have been submitted for regulatory review. The development and testing of generic disease-modifying therapies for MS such as glatiramer acetate, which are complex molecules, present several complicating factors. SUMMARY: This article provides background on the development of generics and reviews the status of generic glatiramer acetate.
Authors: Maria Pia Sormani; Laura Bonzano; Luca Roccatagliata; Gary R Cutter; Gian Luigi Mancardi; Paolo Bruzzi Journal: Ann Neurol Date: 2009-03 Impact factor: 10.422
Authors: Daniel D Mikol; Frederik Barkhof; Peter Chang; Patricia K Coyle; Douglas R Jeffery; Steven R Schwid; Bettina Stubinski; Bernard M J Uitdehaag Journal: Lancet Neurol Date: 2008-09-11 Impact factor: 44.182
Authors: G Comi; V Martinelli; M Rodegher; L Moiola; O Bajenaru; A Carra; I Elovaara; F Fazekas; H P Hartung; J Hillert; J King; S Komoly; C Lubetzki; X Montalban; K M Myhr; M Ravnborg; P Rieckmann; D Wynn; C Young; M Filippi Journal: Lancet Date: 2009-10-06 Impact factor: 79.321
Authors: Jeffrey Cohen; Anna Belova; Krzysztof Selmaj; Christian Wolf; Maria Pia Sormani; Janine Oberyé; Evelyn van den Tweel; Roel Mulder; Norbert Koper; Gerrit Voortman; Frederik Barkhof Journal: JAMA Neurol Date: 2015-12 Impact factor: 18.302